• Home
• People
• Bio
• Aze Wilson

Aze Wilson

Dr. Aze Wilson is a clinical gastroenterologist and an Assistant Professor of Medicine at Western University. She joined the Division of Gastroenterology in 2016 as a Clinician-Researcher with a focus on translational research in inflammatory bowel disease. She also has a cross-appointment with the Division of Clinical Pharmacology and the Department of Physiology & Pharmacology.  Dr. Wilson began her scientific training at Queen's University, where she completed an honours BSc. in Life Sciences.  She completed her medical education at Western University, becoming accredited in both Internal Medicine and Gastroenterology.  She completed the Royal College-certified Clinician-Investigator Program in 2016 in addition to completing her PhD in Physiology and Pharmacology. Her clinical interests include inflammatory bowel disease and other luminal diseases. Her research interests include drug metabolism and drug response in inflammatory bowel disease, with a particular focus on genetic markers of drug response.

Selected Publications 

Rahman S, McDonald C, Cipriano LE, Cocco S, Hindi Z, Chakraborty D, French K, Siddiqi O, Blier M, Brahmania M, Wilson A, Yan B, Guizzetti L, Jairath V, Sey M. Propofol sedation does not improve measures of colonoscopy quality but increase cost – Findings from a large population-based cohort study. eClinicalMedicine. 2024. Co-author [accepted in press].

Choi J, Wang Q, Beaton M, Kim RB, Khanna R, Wilson A. Infliximab tissue levels in patients with stable ulcerative colitis are correlated with more durable infliximab-associated disease remission. Inflammatory Bowel Diseases. 2024. Senior Author [revisions].

Wilson A, Chande N, Ponich J, Gregor J, Choi Y, Kim RB. HLADQA1*05 genetic-screening for the safe delivery of combination therapy in inflammatory bowel disease. Clinical Gastroenterol and Hepatol 2023. Principal author [accepted, in press] impact factor 13.576.

Solitano V; Facciorusso A; McGovern DPB; Nguyen T; Colman RJ; Zou L;. BOLAND BS; Syversen SW; Kaasen Jørgensen D; Ma C; Armuzzi A; Wilson A; Jairath V; Singh S. HLA-DQA1*05 Genotype and Immunogenicity to Tumor Necrosis Factor-α Antagonists: A Systematic Review and Meta-analysis. Clinical Gastroenterol Hepatol. 2023 Apr 13;S1542-3565(23)00270-7. doi: 10.1016/j.cgh.2023.03.044 PMID 37061107. Co-author

Arora A, MacDonald C, Guizetti L, Iansavitchene A, Brahmania M, Khanna N, Wilson A, Jairath V, Sey M. Endoscopy unit level interventions to improve adenoma detection rate– a systematic review and meta-analysis of the literature. Clinical Gastroenterol and Hepatol 2023 Apr 18;S1542-3565(23)00276-8.; doi: 10.1016/j.cgh.2023.03.049. PMID 37080261. Co-author

Choi B, Sey M, Ponich T, Beaton M, Kim RB, Wilson A. Maintenance phase infliximab trough concentrations are associated with a variable number tandem repeat polymorphism in the neonatal Fc receptor. Inflammatory bowel diseases. September 2022. PMID 36112504. Senior author

Wilson, A. Editorial: The Immunogenicity to Second Anti-TNF Therapy (IMSAT) therapeutic drug monitoring study – defining the risk of the in-class switch. Alimentary Pharmacology & Therapeutics. August 2022. Principal author

Sey M, Cocco S, McDonald C, Hindi Z, Rahman H, Chakraborty D, French K, Alsager M, Siddiqi O, Blier M, Markandey B, Al Obaid S, Wong A, Siebring V, Brahmania M, Gregor J, Khanna N, Ott M, Qumosani K, Wilson A, Guizzetti L, Yan B, Jairath V. Association of Trainee Participation in Colonoscopy Procedures with Quality Metrics. JAMA Network Open. 2022;5(8):e2229538. doi:10.1001/jamanetworkopen.2022.29538. Co-author

Sedano R, Guizzetti L, McDonald C, Beaton M, Chande N, Gregor J, Sey M, Wilson A, Jairath V. Clinical, endoscopic and radiological effectiveness of ustekinumab in bio-naïve versus bio-experienced patients with Crohn’s disease: real-world experience from a large Canadian centre. Inflammatory bowel diseases. Inflammatory Bowel Diseases July 2022. Co-author

Malhi G, Minhas G, Chambers J, Mikail M, Khanna R, Wilson A. Increased Hospitalization for IBD Patients Seen in the ER During the COVID-19 Pandemic. Journal of the Canadian Association of Gastroenterology. 2022 Jun 25. Senior author.

Almaghrabi M, Gandhi M, Guizzetti L, Iansavichene A, Yan B, Wilson A, Oakland K, Jairath V, Sey M. Diagnostic performance of lower gastrointestinal bleeding risk scores-A systematic review and meta-analysis. JAMA Netw Open. 2022 May 2;5(5):e2214253. doi: 10.1001/jamanetworkopen.2022.14253. PMID: 35622365; PMCID: PMC9142877. Co-author

Wilson A, Kim RB. Correspondence: Failure to Achieve Target Drug Concentrations During Induction and Not HLA- DQA1*05 Carriage is Associated with Anti-Drug Antibody Formation in Patients with Inflammatory Bowel Disease - Is HLADQA1*05 gone before it's here? Gastroenterology. 2022 Apr 12:S0016-5085(22)00367-5. doi: 10.1053/j.gastro.2022.04.011. PMID: 35427575. First Author

Townsend CM, Lovegrove F, Khanna R, Wilson A. Review article: Paradoxical psoriasis as a consequence of Tumor Necrosis Factor alpha inhibitors in patients with Inflammatory Bowel Disease. Aliment Pharmacol Ther. March 21, 2022. Senior Author.

Chambers J, Malhi G, Mikail M, Minot G, Khanna R, Wilson A. Short-term COVID-19-related delays in endoscopy are not associated with deleterious outcomes in inflammatory bowel disease. Journal of Canadian Association of Gastroenterology. 2022. Senior Author.

Guo A, Ross C, Chande N, Gregor J, Ponich T, Khanna R, Beaton M, Kim RB, Wilson A. High Oncostatin-M predicts non-response to anti-TNF-α drugs in inflammatory bowel disease. Scientific Reports. 2022 Jan 24;12(1):1185.doi: 10.1038/s41598-022-05208-9. Senior author. PMID35075155

Wang Q, Mailloux J, Schwarz UI, Kim RB, Wilson A. A novel NUDT15 variant identified in Caucasian TPMT wild type patients with inflammatory bowel disease and azathioprine-related myelotoxicity. Pharmacogenetics and Genomics. Jan 1 2022. PMID: 34751173. Senior Author

Khanna R, Wilson A, Gregor JC, Prowse K, Waqqas A. Clinical Guidelines for the Management of IBD. Gastroenterology. Sept 14 2021. PMID: 34534537 DOI: 10.1053/j.gastro.2021.09.021; Co-Author.

Heath EM, Kim RB, Wilson A. A comparative analysis of drug therapy, disease phenotype, and health care outcomes for men and women with inflammatory bowel disease. Digestive Diseases and Sciences. Dig Dis Sci. 2021 Jul 27. doi: 10.1007/s10620-021-07177-x. PMID: 34313923. Senior Author

Cheah M, Wilson A, Solh Z, Khanna R. IgA-Mediated Warm Autoimmune Hemolytic Anemia as an Extraintestinal Manifestation in a Patient With Crohn Disease on Vedolizumab. Inflamm Bowel Dis. 2021 May 18:izab090. doi: 10.1093/ibd/izab090. Epub ahead of print. PMID: 34003281.

Wilson A, Kim RB. Letter: genetic variation in the HLA-DQA1*05 allele predicts tumour necrosis factor-α antagonist immunogenicity - does location matter? Aliment Pharmacol Ther. 2021 May;53(9):1055-1056. doi: 10.1111/apt.16338. PMID: 33831241.

Mikail M, Wilson A. Low Serum Tumor Necrosis Factor-α Antagonist Concentrations in Patients With Inflammatory Bowel Disease Who Achieve Healing From Pyoderma Gangrenosum, Inflamm Bowel Dis, 2021;izab148, https://doi.org/10.1093/ibd/izab148

Townsend C, Khanna R, Wilson A. A more severe non-melanoma skin cancer phenotype is seen in patients with inflammatory bowel disease on tumor necrosis factor-α antagonists. Digestive Diseases & Sciences, 2021Jan 11. doi: 10.1007/s10620-020-06773-7. Senior Author

Wilson A, Wang Q, Choi Y, Ponich T, Gregor JC, Chande N, Yan B, Sey M, Beaton M, Kim RB. Pre-treatment HLADQA1-HLADRB1 testing for the prevention of azathioprine-induced pancreatitis in inflammatory bowel disease: a prospective cohort study. Clinical & Translational Gastroenterology, April 2021; 12 (4) doi: 10.14309/ctg.0000000000000332. Principal Author

Wilson A, Choi B, Sey M, Ponich T, Beaton M, Kim RB. High infliximab trough concentrations are associated with sustained histologic remission in inflammatory bowel disease. BMC Gastroenterology, 21, 77 (2021). https://doi.org/10.1186/s12876-021-01650-7. Principal Author

Imasogie N, Rose RV, Wilson A. High Quantities: Evaluating the Effect of Cannabis Use on Propofol Anesthesia during Endoscopy. PLOS One, March 4 2021, 16(3): e0248062. https://doi.org/10.1371/journal.pone.0248062. Senior Author

Mikail M, Wilson A. Infliximab exposure in large, multifocal, abdominal pyoderma gangrenosum associated with ulcerative colitis: a case report. Sage Open Medical Case Reports, 2020 October 23, Senior Author doi: 10.1177/2050313X20964113 PMID: 33149915

Wilson A, Beaton MD, Brahmania M. Letter to the editor: non-alcoholic fatty liver disease - one size may not fit all. Hepatology. 2020 Sep 23. doi: 10.1002/hep.31564. Epub ahead of print. PMID: 32965684, Impact Factor: 14.7, Principal Author

Wilson A, Wang Q, Almousa AA, Jansen LE, Choi Y, Schwarz UI, Kim RB. Genetic variation in the Farnesoid X-Receptor Predicts Crohn’s Disease Severity in Female Patients. Scientific Reports, 2020 Jul; 10(1):11725, Principal Author, doi:10.1038/s41598-020-68686-9

Al Draiweesh S, Ma C, Alkhattabi M, McDonald C, Nguyen TM, Beaton M, Chande N, Colquhoun P, Feagan BG, Gregor JC, Khanna R, Marotta P, Ponich T, Quan D, Qumosani K, Sandhu A, Sey M, Skaro A, Teriaky A, Wilson A, Yan B, Brahmania M, Jairath V. Safety of Combination Biologic and Antirejection Therapy Post-Liver Transplantation in Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis, 2020 Jun; 26(6):949-59, Coauthor, DOI: 10.1093/ibd/izz244.

Wilson A, Peel C, Wang Q, Pananos AD, Kim RB. Letter: immunogenicity of infliximab—ready for routine prediction? Authors’ reply. Alimentary Pharmacology & Therapeutics. 2020 Mar 30, 51. (18): p.813-814, Principal Author, DOI: doi.org/10.1111/apt.15684

Wilson A, Peel C, Wang Q, Pananos AD, Kim RB. HLADQA1*05 genotype predicts anti-drug antibody formation and loss of response during infliximab therapy for inflammatory bowel disease. Aliment Pharmacol Ther, 2020 Feb; 51(3):356-363, Principal Author, DOI: 10.1111/apt.15563.

Wilson A, Almousa A, Teft WA, Kim RB. Attenuation of bile acid-mediated FXR and PXR activation in patients with Crohn’s disease. Sci Rep, 2020 Feb 5; 10 (1): 1866, Principal Author, DOI: 10.1038/s41598-020-58644-w.

Wilson A, Urquhart BL, Ponich T, Chande N, Gregor JC, Beaton M, Kim RB. Crohn’s Disease Is Associated with Decreased CYP3A4 and P-Glycoprotein Protein Expression. Mol Pharm, 2019 Sep 3; 16 (9): 4059-4064, Principal Author, DOI: 10.1021/acs.molpharmaceut.9b00459.

Zhu CN, Friedland J, Yan B, Wilson A, Gregor J, Jairath V, Sey M. Presence of Melena in Obscure Gastrointestinal Bleeding Predicts Bleeding in the Proximal Small Intestine. Dig Dis Sci, 2018 May 1; 63 (5): 1280-1285, Coauthor, DOI: 10.1007/s10620-018-5003-x.

Wilson A, Jansen LE, Rose RV, Gregor JC, Ponich T, Chande N, Khanna R, Yan B, Jairath V, Khanna N, Sey M, Beaton M, McIntosh K, Teft WA, Kim RB. Letter: predicting azathioprine-associated pancreatitis in IBD-phenotype or genotype? Authors’ reply. Aliment Pharmacol Ther. 2018 Apr 1, 47. (7): p.1044-1045, First author, DOI: 10.1111/apt.14562.

Wilson A, Jansen LE, Rose RV, Gregor JC, Ponich T, Chande N, Khanna R, Yan B, Jairath V, Khanna N, Sey M, Beaton M, McIntosh K, Teft WA, Kim RB. HLA-DQA1-HLA-DRB1 polymorphism is a major predictor of azathioprine-induced pancreatitis in patients with inflammatory bowel disease. Aliment Pharmacol Ther, 2018 Mar 1; 47 (5): 615-620, Principal Author, DOI: 10.1111/apt.14483.

Wilson A, Tirona RG, Kim RB. CYP3A4 Activity is Markedly Lower in Patients with Crohn’s Disease. Inflamm Bowel Dis, 2017 Mar 15, Principal Author, DOI: 10.1097/MIB.0000000000001062.

Teft WA, Morse BL, Leake BF, Wilson A, Mansell SE, Hegele RA, Ho RH, Kim RB. Identification and Characterization of Trimethylamine-N-oxide Uptake and Efflux Transporters. Mol Pharm, 2017 Jan 3; 14 (1): 310-318, Co-Author, DOI: 10.1021/acs.molpharmaceut.6b00937.

McLean C, Wilson A, Kim RB. Impact of Transporter Polymorphisms on Drug Development: Is It Clinically Significant? J Clin Pharmacol, 2016 Jul 1; 56 Suppl 7: S40-58, Coauthor, DOI: 10.1002/jcph.691.

Wilson A, McLean C, Kim RB. Trimethylamine-N-oxide: a link between the gut microbiome, bile acid metabolism, and atherosclerosis. Curr Opin Lipidol, 2016 Apr 1; 27 (2): 148-54, Principal Author, DOI: 10.1097/MOL.0000000000000274.

Wilson A, Teft WA, Morse BL, Choi YH, Woolsey S, DeGorter MK, Hegele RA, Tirona RG, Kim RB. Trimethylamine-N-oxide: A Novel Biomarker for the Identification of Inflammatory Bowel Disease. Dig Dis Sci, 2015 Dec 1; 60 (12): 3620-30, Principal Author, DOI: 10.1007/s10620-015-3797-3.

Wilson A, Delport J, Ponich T. Candida glabrata esophagitis: are we seeing the emergence of a new azole-resistant pathogen? International Journal of Microbiology, 2014 Dec; 2014 (2014): Principal Author.

Wilson A, Kim RB. OATP transporters: Potential targets for enhancing organ and tissue specific drug delivery. Journal of Pharmacology and Clinical Toxicology, 2014 Nov; 2 (3): 1037-47, Principal Author

Wilson A, Basharat P, Levstik M, Barra L. Transient elastography for monitoring of liver fibrosis in methotrexate-treated patients with inflammatory disorders: Systematic Review. Autoimmune Diseases and Clinical Therapeutics, 2014 Oct; 1 (2): 104-110, Co-Principal Author

Wilson A, Patel V, Chande N, Ponich T, Urquhart B, Asher L, Choi Y, Tirona R, Kim RB, Gregor JC. Pharmacokinetic profiles for oral and subcutaneous methotrexate in patients with Crohn’s disease. Aliment Pharmacol Ther, 2013 Feb 1; 37 (3): 340-5, Principal Author, DOI: 10.1111/apt.12161.